Biomedical Engineering Reference
In-Depth Information
[132] Muranishi S, Murakami M, Hashidzume M, Yamada K, Tajima S, Kiso Y. Trials of
lipid modification of peptide hormones for intestinal delivery. J Control Release
1992;19:179-88.
[133] Tanaka K, Fujita T, Yamamoto Y, Murakami M, Yamamoto A, Muranishi S. Enhancement
of intestinal transport of thyrotropin-releasing hormone via a carrier-mediated transport sys-
tem by chemical modification with lauric acid. Biochim Biophys Acta 1996;1283:119-26.
[134] Muranishi S, Sakai A, Yamada K, Murakami M, Takada K, Kiso Y. Lipophilic peptides:
synthesis of lauroyl thyrotropin-releasing hormone and its biological activity. Pharm
Res 1991;8:649-52.
[135] Fujita T, Morikawa K, Iemura O, Yamamoto A, Muranishi S. Improvement of intestinal
absorption of human calcitonin by chemical modification with fatty acids: synergistic
effects of acylation and absorption enhancers. Int J Pharm 1996;134:47-57.
[136] Tenma T, Yodoya E, Tashima S, Fujita T, Murakami M, Yamamoto A, et al.
Development of new lipophilic derivatives of tetragastrin: physicochemical character-
istics and intestinal absorption of acyl-tetragastrin derivatives in rats. Pharm Res 1993;
10:1488-92.
[137] Yodoya E, Uemura K, Tashima S, Fujita T, Murakami M, Yamamoto A, et al.
Enhancement permeability of tetragastrin across the intestinal membrane and its
reduced degradation by Acylation with various fatty acids in rats. J Pharmacol Exp Ther
1994;271:1509-13.
[138] Setoh K, Murakami M, Araki N, Fujita T, Yamamoto A, Muranishi S. Improvement of
transdermal delivery of tetragastrin by lipophilic modification with fatty acids. J Pharm
Pharmacol 1995;47:808-11.
[139] Fujita T, Kawahara I, Quan Y, Hattori K, Takenaka K, Muranishi S, et al. Permeability
characteristics of tetragastrins across intestinal membranes using the CACO-2 mono-
layer system: comparison between acylation and application of protease inhibitors.
Pharm Res 1998;15:1387-92.
[140] Murakami M, Kotani A, Uchiyama T, Fujita T, Yamamoto A, Muranishi S. Enteric pep-
tide delivery by chemical modification with fatty acids: epithelial permeability enhance-
ment of Dadle. Proc Int Symp Control Release Bioact Mater 1997;24:349-50.
[141] Stoughton RB, McClure WO. Azone, a new non toxic enhancer of cutaneous penetra-
tion. Drug Dev Ind Pharm 1983;9:725-44.
[142] Bundgaard H, Moss J. Prodrugs of peptides (part 4): bioreversible derivatization of the
pyroglutamyl group by N-acylation and N-aminomethylation, effect protection against
pyroglutamyl aminopeptidase. J Pharm Sci 1989;78:122-6.
[143] Veillard MM, Longer MA, Robinson JR. Buccal controlled delivery of peptides. Proc
Int Symp Control Release Bioact Mater 1987;14:22.
[144] Veillard MM, Longer MA, Martens TW, Robinson JR. Preliminary studies of oral
mucosal delivery of peptide drugs. J Control Release 1987;6:123-31.
[145] Veuillez F, Ganem-Quintanar A, Deshusses J, Falson-Rieg F, Buri P. Comparison of
the ex-vivo oral mucosal permeation of tryptophan-leucine (Trp-Leu) and its myristoyl
derivative. Int J Pharm 1998;170:85-91.
[146] Kahns AH, Bundgaard H. Prodrugs of peptides. 13. Stabilization of peptide amides
against a-chymotrypsin by the prodrug approach. Pharm Res 1991;8:1533-8.
[147] Buur A, Bundgaard H. Prodrugs of peptides. III. 5-oxazolidinones as bioreversible
derivatives for the x-amido carboxy moiety in peptides. Int J Pharm 1988;46:159-67.
[148] Shen W, Wan J, Ekrami H. C) Means to enhance penetration: (3) Enhancement of poly-
peptide and protein absorption by macromolecular carriers via endocytosis end trans-
cytosis. Adv Drug Deliv Rev 1992;8:93-113.
Search WWH ::
Custom Search